Ultibro Breezhaler

Ultibro Breezhaler Overdosage

indacaterol + glycopyrronium

Manufacturer:

Novartis

Distributor:

DKSH
Full Prescribing Info
Overdosage
There is no information on clinically relevant overdosing with Ultibro Breezhaler.
An overdose could lead to exaggerated effects typical of beta2-adrenergic stimulants, i.e. tachycardia, tremor, palpitations, headache, nausea, vomiting, drowsiness, ventricular arrhythmias, metabolic acidosis, hypokalaemia and hyperglycaemia or could induce anticholinergic effects such as increased intraocular pressure (causing pain, vision disturbances or reddening of the eye), obstipation or difficulties in voiding. Supportive and symptomatic treatment is indicated. In serious cases, patients should be hospitalised. Use of cardioselective beta blockers may be considered for treating beta2-adrenergic effects, but only under the supervision of a physician and with extreme caution since the use of beta-adrenergic blockers may provoke bronchospasm.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in